tian jin medical university
Tianjin & AstraZeneca Collaborate On Cardiovascular Disease
Tianjin Medical University and Astrazeneca will collaborate to develop soluble epoxide hydrolase inhibitors for the treatment of cardiac fibrosis.
Tianjin Medical University and Astrazeneca will collaborate to develop soluble epoxide hydrolase inhibitors for the treatment of cardiac fibrosis.
